Motivated by recent advances in the field, this review explores the current frontier of cancer nanomedicine. Nanomedicines have supported chemotherapy, phototherapy and sonodynamic therapy, nucleic acid therapy, and immunotherapy. However, translating nanomedicines into practice has been challenged by complex...
Over the last few decades, advances in molecular cell biology have greatly contributed to our knowledge of the molecular mechanisms of tumorigenesis and its progression, which in turn provides opportunities for the development of novel molecular targeted agents that inhibit molecular abnormalities as promi...
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials Article Open access 23 September 2020 Engineering protein-based therapeutics through structural and chemical design Article Open access 27 April 2023 New insights into protein–protein interactio...
Over the last few decades, advances in molecular cell biology have greatly contributed to our knowledge of the molecular mechanisms of tumorigenesis and its progression, which in turn provides opportunities for the development of novel molecular targeted agents that inhibit molecular abnormalities as promi...
Editorial [Hot Topic:Recent Advances in Developmental and Reproductive Toxicology (Executive Editor: Gian Mario Tiboni )]Cleft lipThis collection of papers focuses on environmental forces and their noxious influences on reproductive processes and intrauterine life. In line with previous journal initiatives ...
A retrospective study evaluated 23 patients with IVC stage ATC treated with Lenvatinib. Ten patients previously underwent surgery, the remaining having not received any prior treatment. The ORR was 23.5% and the DCR was 58.8%. The median OS was 5.5 months and it was longer in the group of ...
Recent advances in siRNA delivery mediated by lipid-based nanoparticles Author links open overlay panelSei Yonezawa, Hiroyuki Koide, Tomohiro AsaiShow more Add to Mendeley Share Cite https://doi.org/10.1016/j.addr.2020.07.022Get rights and content...
Targeting TIGIT for cancer immunotherapy: recent advances and future directions Abstract As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+T cells, CD8+T cells, natural killer (NK) cells,...
(DCR) was 62.5% (15/24). Furthermore, the ORR was 50% (2/4) in four evaluated HL patients who received TTI-621 in combination with nivolumab. Another study enrolled 14 patients with R/R lymphoma to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and ...
With the same momentum, recent advances in immune checkpoint blockade therapy have achieved remarkable results by the relevant nanotechnology, such as nano-encapsulated immune checkpoint inhibitor, nano-delivery PDL1 siRNA, and the combination of immune checkpoint inhibitor and nanoparticle-encapsulated ...